Based on these findings, therapeutic strategies targeting these immune pathways—especially IL-17, TNF, and IL1B—could hold promise for the development of treatments that simultaneously address both IBD and chronic periodontitis, offering a more integrated approach to managing these co-occurring diseases. This evidence concerns the gene IL1B and inflammatory bowel disease.